股票代码：000039、299901 股票简称：中集集团、中集 H 代 公告编号：【CIMC】2025-092 中国国际海运集装箱（集团）股份有限公司 关于首次回购部分 A 股股份暨进展公告 截至 2025 年 9 月 30 日，公司未实施本次 A 股股份回购。 2025 年 10 月 9 日，公司通过集中竞价交易方式首次回购公司 A 股股份 2,410,750 股，占公司截至本公告日总股本的比例为 0.0447%，购买的最高价为人民币 8.37 元/ 股，最低价为人民币 8.25 元/股，已使用的资金总额为人民币 19,999,506 元（不含交 易费用）。上述回购符合公司既定的回购股份方案。 公司后续将根据实施回购股份的进展情况，严格按照相关法律、法规和规范性文 件等规定，及时履行信息披露义务，敬请广大投资者注意投资风险。 1 特此公告。 中国国际海运集装箱（集团）股份有限公司 董事会 二〇二五年十月九日 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 中国国际海运集装箱（集团）股份有限公司（以下简称"公司"或"本公司"） 于 2025 年 9 月 29 日 ...

中集集团公告，2025年10月9日，公司通过集中竞价交易方式首次回购公司A股股份241.07万股，占公司 截至本公告日总股本的比例为0.0447%，购买的最高价为人民币8.37元/股，最低价为人民币8.25元/股， 已使用的资金总额为人民币1999.95万元（不含交易费用）。截至2025年9月30日，公司未实施本次A股 股份回购。 ...

Group 1 - On October 9, CIMC Group executed a block trade of 450,100 shares, with a transaction amount of 3.6367 million yuan, accounting for 0.7% of the total trading volume for the day [1][2] - The transaction price was 8.08 yuan per share, which represents a discount of 3.58% compared to the market closing price of 8.38 yuan [1][2]

香港交易及結算所有限公司及香港聯合交易所有限公司（「香港聯交所」）對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 中國國際海運集裝箱（集團）股份有限公司 CHINA INTERNATIONAL MARINE CONTAINERS (GROUP) CO., LTD. （於中華人民共和國註冊成立之股份有限公司） (股份代號：02039) 海外監管公告 本公告乃中國國際海運集裝箱（集團）股份有限公司（「公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10B 條作出。 茲載列公司在公司網站（www.cimc.com）以及巨潮資訊網（www.cninfo.com.cn）刊登 的《中國國際海運集裝箱（集團）股份有限公司關於回購股份事項前十大股東和前十大 無限售條件股東持股情況的公告》，僅供參閱。 承董事會命 中國國際海運集裝箱（集團）股份有限公司 吳三強 公司秘書 香港，2025 年 10 月 8 日 於本公告日期，本公司董事會成員包括：執行董事麥伯良先生（董事長），非執行董事 朱志強先生（副董事長 ...

证券代码：000039、299901 证券简称：中集集团、中集 H 代 公告编号：【CIMC】2025-091 中国国际海运集装箱（集团）股份有限公司 关于按照《香港上市规则》公布 2025年9月份证券变动月报表的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、 误导性陈述或重大遗漏。 中国国际海运集装箱（集团）股份有限公司根据《香港联合交易所有限公司证券 上市规则》（简称"《香港上市规则》"）规定，在香港联合交易所有限公司披露易 网站（www.hkexnews.hk）刊登了截至2025年9月30日的证券变动月报表。 根据《深圳证券交易所股票上市规则》关于境内外同步披露的要求，特将有关公 告同步披露如下，供参阅。 特此公告。 肤撞：新提交 致：香港交易及结算所有限公司 公司名稿： 中圄圃隙海逼集装箱（集圄）股份有限公司 呈交日期： 2025年10月8日 I.法定／自主阳股本蟹勤 口不通用 | 1. 股份分颊 | 普通股 | 股份额别 | H | ｜於香港聊交所上市｛盐1) | | | 日 | | --- | --- | --- | --- | --- | --- | --- | - ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02039 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,089,837,895 | RMB | | 1 RMB | | 3,089,837,895 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 3,089,837,895 | RMB | | 1 RMB | | 3,089,837,895 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | - ...

中国国际海运集装箱（集团）股份有限公司 关于回购股份事项前十大股东和前十大无限售条件股东 持股情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 中国国际海运集装箱（集团）股份有限公司（以下简称"公司"或"本公司"）于 2025 年 9 月 29 日召开了第十一届董事会 2025 年度第 10 次会议，审议通过了《关于回 购部分 A 股股份方案的议案》，具体内容详见公司于 2025 年 9 月 30 日在巨潮资讯网 （www.cninfo.com.cn）、本公司网站（www.cimc.com）披露的公告（公告编号：【CIMC】 2025-088 及【CIMC】2025-089）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— —回购股份》等相关规定，现将 2025 年 9 月 29 日登记在册的前十大股东和前十大无限 售条件股东的名称、持股数量和持股比例等情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例 | 股份种类 | | --- | --- | --- | --- | --- | | 1 | ...

Group 1 - Company announced a share buyback plan during the 10th meeting of the 11th Board of Directors on September 29, 2025 [1] - The top ten unrestricted shareholders hold approximately 38.75 billion shares, accounting for 71.88% of total shares [1] - Major shareholders include Hong Kong Central Clearing with about 3.141 billion shares (58.25%) and Shenzhen Liyue Industrial Group with about 275 million shares (5.1%) [1] Group 2 - For the first half of 2025, the revenue composition of the company is as follows: containers 27.7%, logistics services 17.68%, energy and chemical equipment 16.88%, road transport vehicles 11.15%, marine engineering 10.44%, and other industries 6.87% [2] - The current market capitalization of the company is 44.7 billion yuan [2]

Core Viewpoint - China International Marine Containers (Group) Co., Ltd. (CIMC) has approved a plan to repurchase a portion of its A-shares to enhance company value and protect shareholder interests [3][6][19]. Group 1: Board Meeting Details - The 10th meeting of the 11th Board of Directors for the year 2025 was held on September 29, 2025, via written communication, with all nine directors participating [2][5]. - The meeting complied with relevant regulations including the Company Law and Securities Law of the People's Republic of China [2]. Group 2: Share Repurchase Plan - The company plans to use its own funds to repurchase A-shares, with a total repurchase amount not exceeding RMB 5 billion and not less than RMB 3 billion [6][11]. - The maximum repurchase price is set at RMB 12.01 per share, with an estimated repurchase quantity ranging from approximately 2.5 million to 4.16 million shares, representing 0.46% to 0.77% of the total issued share capital [6][11][12]. - The repurchased shares will be used to maintain company value and shareholder rights, with potential future adjustments for employee stock ownership plans or equity incentives [9][19]. Group 3: Implementation and Authorization - The authorization for the repurchase is effective from the date of the board's approval until the completion of the related matters [4][22]. - The board has authorized the chairman or designated personnel to manage the repurchase process, including deciding on the specific plan, timing, and scale [3][22]. Group 4: Financial Impact and Conditions - As of June 30, 2025, the company's total assets were approximately RMB 175.44 billion, with cash and cash equivalents around RMB 26.06 billion, indicating that the repurchase amount will not significantly impact the company's financial stability [17][18]. - The repurchase is expected to be completed within three months from the board's approval, with provisions for extension if necessary [13][14]. Group 5: Disclosure and Compliance - The company will disclose the progress of the repurchase regularly, including any adjustments to the use of repurchased shares [24]. - There are no current plans for share reduction by major shareholders or management, ensuring compliance with relevant regulations [19][20].

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]